Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting.


Journal

The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617

Informations de publication

Date de publication:
12 08 2021
Historique:
received: 03 02 2021
accepted: 21 04 2021
pubmed: 29 6 2021
medline: 28 10 2021
entrez: 28 6 2021
Statut: ppublish

Résumé

This systematic review focuses on the use of the in vitro hollow fibre infection model (HFIM) for microbial culture. We summarize the direction of the field to date and propose best-practice principles for reporting of the applications. Searches in six databases (MEDLINE®, EMBASE®, PubMed®, BIOSIS®, SCOPUS® and Cochrane®) up to January 2020 identified 129 studies meeting our inclusion criteria. Two reviewers independently assessed and extracted data from each publication. The quality of reporting of microbiological and technical parameters was analysed. Forty-seven out of 129 (36.4%) studies did not report the minimum pharmacokinetic parameters required in order to replicate the pharmacokinetic profile of HFIM experiments. Fifty-three out of 129 (41.1%) publications did not report the medium used in the HFIM. The overwhelming majority of publications did not perform any technical repeats [107/129 (82.9%)] or biological repeats [97/129 (75.2%)]. This review demonstrates that most publications provide insufficient data to allow for results to be evaluated, thus impairing the reproducibility of HFIM experiments. Therefore, there is a clear need for the development of laboratory standardization and improved reporting of HFIM experiments.

Identifiants

pubmed: 34179966
pii: 6310347
doi: 10.1093/jac/dkab160
pmc: PMC8361333
doi:

Substances chimiques

Anti-Bacterial Agents 0
Anti-Infective Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2252-2259

Subventions

Organisme : Medical Research Council
ID : MR/N025989/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : P014534
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M008665/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 220587/Z/20/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.

Auteurs

Zahra Sadouki (Z)

Institute for Global Health, University College London, London, UK.
Centre of Clinical Microbiology, University College London, London, UK.

Timothy D McHugh (TD)

Centre of Clinical Microbiology, University College London, London, UK.

Rob Aarnoutse (R)

Department of Internal Medicine, Radboud Center of Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands.

Julio Ortiz Canseco (J)

Centre of Clinical Microbiology, University College London, London, UK.

Christopher Darlow (C)

Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, UK.

William Hope (W)

Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, UK.

Jakko van Ingen (J)

Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.

Christopher Longshaw (C)

Medical Affairs, Shionogi Europe, London, UK.

Davide Manissero (D)

Medical Affairs for Infection and Immune Diagnostics, QIAGEN, London, UK.

Andrew Mead (A)

Department of Comparative Biological Sciences, The Royal Veterinary College, London, UK.

Ludovic Pelligand (L)

Department of Comparative Biological Sciences, The Royal Veterinary College, London, UK.

Lynette Phee (L)

Antimicrobial Research Group, Barts and The London School of Medicine and Dentistry, Queen Mary University London, London, UK.

John Readman (J)

Infection, Immunity, Inflammation Section, University College London Great Ormond Street Institute of Child Health, London, UK.

Mike M Ruth (MM)

Department of Internal Medicine, Radboud Center of Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands.

Joseph F Standing (JF)

Infection, Immunity, Inflammation Section, University College London Great Ormond Street Institute of Child Health, London, UK.

Neil Stone (N)

Department of Microbiology, University College London Hospitals, London, UK.

Emmanuel Q Wey (EQ)

Royal Free London NHS Trust, London, UK.

Frank Kloprogge (F)

Institute for Global Health, University College London, London, UK.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents
Humans Middle Aged Female Male Surveys and Questionnaires

Classifications MeSH